https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-04-21 / J Pharm Anal 2023 Jun;13(6):616-624
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-04-21 / J Pharm Anal 2023 Jun;13(6):616-6242023-04-21 00:00:002023-04-21 00:00:00Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-04-12 / Biomed Pharmacother 2023 Jun;162:114685
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-04-12 / Biomed Pharmacother 2023 Jun;162:1146852023-04-12 00:00:002023-04-12 00:00:00Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-04-10 / Genes (Basel) 2023 Apr;14(4)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-04-10 / Genes (Basel) 2023 Apr;14(4)2023-04-10 00:00:002023-04-10 00:00:00Transcriptome Analysis of Natural Killer Cells in Response to Newcastle Disease Virus Infected Hepatocellular Carcinoma Cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-04-04 / J Cancer Metastasis Treat 2023;9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-04-04 / J Cancer Metastasis Treat 2023;92023-04-04 00:00:002023-04-04 00:00:00Immune responses elicited by ssRNA(-) oncolytic viruses in the host and in the tumor microenvironment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-04-03 / Pharmaceutics 2023 Apr;15(4)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-04-03 / Pharmaceutics 2023 Apr;15(4)2023-04-03 00:00:002023-04-03 00:00:00The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-04-01 / J Cancer Res Ther 2023 Apr;19(Supplement):S52-S58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-04-01 / J Cancer Res Ther 2023 Apr;19(Supplement):S52-S582023-04-01 00:00:002023-04-01 00:00:00Personalized dendritic cell vaccination in cancer therapy: An evidence-based research study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-03-15 / Front Cell Infect Microbiol 2023;13:1142172
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-03-15 / Front Cell Infect Microbiol 2023;13:11421722023-03-15 00:00:002023-03-15 00:00:00Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-03-07 / Cancer Immunol Immunother 2023 Mar;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-03-07 / Cancer Immunol Immunother 2023 Mar;2023-03-07 00:00:002023-03-07 00:00:00A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-03-02 / NPJ Vaccines 2023 Mar;8(1):29
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-03-02 / NPJ Vaccines 2023 Mar;8(1):292023-03-02 00:00:002023-05-30 16:16:10Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-02-22 / Cancers (Basel) 2023 Feb;15(5)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-02-22 / Cancers (Basel) 2023 Feb;15(5)2023-02-22 00:00:002023-02-22 00:00:00From Localized Mild Hyperthermia to Improved Tumor Oxygenation: Physiological Mechanisms Critically Involved in Oncologic Thermo-Radio-Immunotherapy
